ROCK HILL, South Carolina and
REHOVOT, Israel, Jan. 13, 2020 /PRNewswire/ -- Today, 3D Systems
(NYSE: DDD) and CollPlant Biotechnologies (NASDAQ:
CLGN), announced signing a joint development agreement
intended to play a pivotal role in advancing and accelerating
breakthroughs in the biomedical industry. The collaboration brings
together two industry pioneers--3D Systems, renowned for its 3D
printing technologies and healthcare expertise; and CollPlant, the
developer of proprietary recombinant human collagen (rhCollagen)
BioInk technology currently used for 3D bioprinting of tissues
and organs. The two companies plan to jointly develop tissue and
scaffold bioprinting processes for third party
collaborators.
3D Systems and CollPlant recognized an unmet market need for a
comprehensive solution to produce tissues and scaffolds for
regenerative medicine applications. The companies intend to create
integrated 3D bioprinting solutions comprised of state-of-the-art
3D bioprinters and BioInks to produce tissues and scaffolds. In
accordance with the collaboration agreement, both companies may use
a combination of 3D Systems' printers, CollPlant's BioInks, and new
formulations of rhCollagen-based BioInks jointly developed by the
companies, for their own products, as well as for deployments with
third parties.
"3D Systems is excited to work with CollPlant to develop
groundbreaking bioprinted tissue and scaffold technologies," said
Chuck Hull, co-founder and chief
technology officer, 3D Systems. "We believe 3D printing to be a key
technology for regenerative medicine, and this collaboration is one
of many we are entering to play an integral role in this exciting
field. Combining our innovative 3D printing technologies with
CollPlant's rhCollagen based BioInks has the potential to make a
significant impact in bioprinting and regenerative medicine."
"We strongly believe that our proven rhCollagen is the finest
building block for regenerative medicine tissues and scaffolds
available today," Yehiel Tal, chief
executive officer of CollPlant, stated. "As the leading additive
manufacturing printing solutions company, 3D Systems is the
perfect partner for us. Together, we can offer the best combined
technology for 3D bioprinting. We are honored to have established
this important collaboration and we look forward to working
together to advance 3D bioprinting technology to the commercial
phase."
About 3D Systems
More than 30 years ago, 3D Systems brought the innovation of 3D
printing to the manufacturing industry. Today, as the leading AM
solutions company, it empowers manufacturers to create products and
business models never before possible through transformed
workflows. This is achieved with the Company's best-of-breed
digital manufacturing ecosystem - comprised of plastic and metal 3D
printers, print materials, on-demand manufacturing services and a
portfolio of end-to-end manufacturing software. Each solution is
powered by the expertise of the company's application engineers who
collaborate with customers to transform manufacturing environments.
3D Systems' solutions address a variety of advanced applications
for prototyping through production in markets such as aerospace,
automotive, medical, dental and consumer goods. More information on
the company is available at www.3dsystems.com.
About CollPlant
CollPlant is a regenerative medicine company focused on 3D
bioprinting of tissues and organs, and medical aesthetics. Our
products are based on our rhCollagen (recombinant human collagen)
that is produced with CollPlant's proprietary plant based genetic
engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks to develop the manufacture of 3D
bioprinted lungs for transplant in humans.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor for Forward-Looking Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's and 3D Systems' objectives,
plans and strategies, as well as statements, other than historical
facts, that address activities, events or developments that
CollPlant and 3D Systems each intends, expects, projects, believes
or anticipates will or may occur in the future. These statements
are often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will,"
"expects," "estimates," "projects," "positioned," "strategy" and
similar expressions and are based on assumptions and assessments
made in light of management's experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such
statements. Many factors could cause CollPlant's and 3D Systems'
actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements,
including, but not limited to, the following: the CollPlant's
history of significant losses and its need to raise additional
capital and its inability to obtain additional capital on
acceptable terms, or at all; CollPlant's and 3D Systems'
expectations regarding the timing and cost of commencing clinical
trials with respect to tissues and organs which are based on its
rhCollagen-based BioInk; the CollPlant's and 3D Systems' or its
business partners ability to obtain favorable pre-clinical and
clinical trial results; regulatory action with respect to
rhCollagen-based BioInk, including but not limited to acceptance of
an application for marketing authorization, review and approval of
such application, and, if approved, the scope of the approved
indication and labeling; commercial success and market acceptance
of the CollPlant's rhCollagen-based BioInk and 3D Systems'
technologies; CollPlant's ability to establish sales and marketing
capabilities or enter into agreements with third parties and its
reliance on third-party distributors and resellers; the CollPlant's
and 3D Systems' ability to establish and maintain strategic
partnerships and other corporate collaborations; CollPlant's and 3D
Systems' reliance on third parties to conduct some aspects of its
product manufacturing; the scope of protection CollPlant and 3D
Systems are able to establish and maintain for intellectual
property rights and the companies' ability to operate their
business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the companies
operate; projected capital expenditures and liquidity; changes in
the companies' strategy; and litigation and regulatory proceedings.
More detailed information about the risks and uncertainties
affecting CollPlant and 3D Systems is contained under the heading
"Risk Factors" included in CollPlant's most recent annual report on
Form 20-F and 3D Systems' most recent annual report on Form 10-K,
and in other periodic filings, that CollPlant and 3D Systems have
filed with the SEC. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's and 3D Systems' current views with respect
to future events, and neither company undertakes, and each company
specifically disclaims, any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
3D Systems Corporation
333 Three D Systems Circle
Rock Hill, SC 29730
www.3dsystems.com
NYSE:DDD
Investor Contact: Email:
investor.relations@3dsystems.com
Media Contact: Nicole
York, Email: press@3dsystems.com
CollPlant
4 Oppenheimer Street
Rehovot
7670104 Israel
www.collplant.com
NASDAQ:CLGN
Investor & Media Contact:
Eran Rotem, Deputy CEO
Email: Eran@CollPlant.com
Tel: +972-73-2325600
View original content to download
multimedia:http://www.prnewswire.com/news-releases/3d-systems-and-collplant-biotechnologies-join-forces-to-accelerate-breakthroughs-in-regenerative-medicine-300985546.html
SOURCE CollPlant